Effects of rosuvastatin on left ventricular cardiac function, arteriosclerotic plaque and high sensitive C-reactive protein in hypertensive patients with mild LDL-C elevation / 南方医科大学学报
Journal of Southern Medical University
;
(12): 588-590, 2010.
Artículo
en Chino
| WPRIM
| ID: wpr-355064
ABSTRACT
<p><b>OBJECTIVE</b>To observe the effect of rosuvastatin on left ventricular cardiac function, arteriosclerotic plaque and high sensitive C-reactive protein (hs-CRP) in hypertensive patients with mild elevation of LDL-C.</p><p><b>METHODS</b>Seventy-nine patients with a SBP of 140-179 mmHg and/or a DBP of 90-109 mmHg and mild elevated LDL-C were treated with rosuvastatin for 12 months (n=40) or not (n=39). The changes of hs-CRP, arteriosclerosis plaque and cardiac function at the end of the 12-months treatment relative to the baseline levels were analyzed.</p><p><b>RESULTS</b>After 12 months of treatment, LDL-C was decreased by 33.2% in rosuvastatin group but remained unchanged in patients without rosuvastatin treatment. The left ventricular peak filling rate (LVPFR) increased significantly from 1.85 to 2.59 (P<0.05) and the serum levels of hs-CRP reduced significantly (P<0.05) after rosuvastatin treatment. The size of the plaques reduced significantly after a 12-month rosuvastatin therapy.</p><p><b>CONCLUSION</b>Rosuvastatin therapy on the basis of conventional anti-hypertensive drugs can obviously improve the left ventricular diastolic function and produce favorable effects on arteriosclerotic plaques.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Patología
/
Arteriosclerosis
/
Pirimidinas
/
Sulfonamidas
/
Sangre
/
Proteína C-Reactiva
/
Función Ventricular Izquierda
/
Inhibidores de Hidroximetilglutaril-CoA Reductasas
/
Usos Terapéuticos
/
Quimioterapia
Tipo de estudio:
Estudio diagnóstico
Límite:
Anciano
/
Femenino
/
Humanos
/
Masculino
Idioma:
Chino
Revista:
Journal of Southern Medical University
Año:
2010
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS